FINAL PROGRAM - Society for Immunotherapy of Cancer
FINAL PROGRAM - Society for Immunotherapy of Cancer
FINAL PROGRAM - Society for Immunotherapy of Cancer
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Poster Listings<br />
99<br />
ANTI-TUMOR ROLE OF INTERFERON-GAMMA<br />
PRODUCING CD1D-RESTRICTED NKT CELLS IN<br />
MURINE MALIGNANT PLEURAL MESOTHELIOMA<br />
Tetsuzo Tagawa, Licun Wu, Zhihong Yun, Katrina Rey- Mcintyre, Marc<br />
de Perrot<br />
Latner Thoracic Surgery Research Laboratories, Toronto General<br />
Research Institute, University <strong>of</strong> Toronto, Toronto, ON, Canada<br />
100<br />
ELEVATED SERUM SOLUBLE CD40 LIGAND<br />
IN CANCER PATIENTS MAY PLAY AN<br />
IMMUNOSUPPRESSIVE ROLE<br />
Tara Talaie 1 , Catherine Jamis 1 , Austin Anderson 1 , Alessandra<br />
Jales 1 , Caroline Jochems 1 , Chiara Intrivici 1 , Kwong Y. Tsang 1 , Ravi<br />
A. Madan 1,2 , James W. Hodge 1 , James L. Gulley 1 , Jeffrey Schlom 1 ,<br />
Jianping Huang 1<br />
1<br />
Laboratory <strong>of</strong> Tumor Immunology and Biology, Center <strong>for</strong> <strong>Cancer</strong><br />
Research, National <strong>Cancer</strong> Institute, National Institutes <strong>of</strong> Health,<br />
Bethesda, MD<br />
2<br />
Medical Oncology Branch, Center <strong>for</strong> <strong>Cancer</strong> Research, National<br />
<strong>Cancer</strong> Institute, National Institutes <strong>of</strong> Health, Bethesda, MD<br />
101<br />
INTERVENTION OF MULTIPLE REGULATORY<br />
RECEPTORS INHIBITS Bim-MEDIATED T CELL<br />
DELETION AND PROMOTES DURABLE ADOPTIVE<br />
IMMUNOTHERAPY FOR CANCER<br />
Melissa M. Berrien 1 , Stephanie R. Jackson 1 , Jennifer M. Meyer 1 , Craig<br />
J. Rouskey 1 , Long M. Nguyen 1 , Hideo Yagita 2 , Philip D. Greenberg 3 ,<br />
Richard J. DiPaolo 1 , Ryan M. Teague 1<br />
1<br />
Molecular Microbiology and Immunology, Saint Louis University School<br />
<strong>of</strong> Medicine, St. Louis, MO<br />
2<br />
Immunology, Juntendo University School <strong>of</strong> Medicine, Tokyo, Japan<br />
3<br />
Immunology, University <strong>of</strong> Washington, Seattle, WA<br />
102<br />
COMBINING IMMUNETHERAPY AND<br />
CHEMOTHERAPY AGAINST CANCER: ADRIAMYCIN<br />
SENSITIZES HUMANTUMORSTO NK AND T CELL<br />
MEDIATED KILLING VIA AUGMENTED TRAIL<br />
SIGNALING<br />
Erik Wennerberg, Dhifaf Sarhan, Andreas Lundqvist<br />
Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden<br />
103<br />
PROCLAIMSM: A PROSPECTIVE OBSERVATIONAL<br />
REGISTRY OF INTERLEUKIN-2 IN CANCER<br />
Michael Wong 3 , Howard Kaufman 1 , Michael Morse 2 , David<br />
McDermott 4 , Douglas Rizzo 5 , Yan Wu 6 , James Lowder 6<br />
1<br />
Rush University Medical Center, Chicago, IL<br />
2<br />
Duke University <strong>Cancer</strong> Center, Durham, NC<br />
3<br />
University <strong>of</strong> Southern Cali<strong>for</strong>nia Norris <strong>Cancer</strong> Hospital, Los Angeles,<br />
CA<br />
4<br />
Beth Israel Deaconess Medical Center, Boston, MA<br />
5<br />
CIBMTR Medical College <strong>of</strong> Wisconsin, Milwaukee, WI<br />
6<br />
Prometheus Laboratories Inc, San Diego, CA<br />
104<br />
DOSE ESCALATION OF ADJUVANT CAP1-6D/<br />
MONTANIDE/GM-CSF VACCINATION IN HIGH<br />
RISK PANCREATIC CANCER: INDUCTION OF CEA-<br />
SPECIFIC CD8+ T CELL RESPONSES AND EARLY<br />
SUGGESTION OF CLINICAL BENEFIT<br />
Yuanyuan Zha 1 , Thomas F. Gajewski 1,2 , Hedy Kindler 2<br />
1<br />
Human Immunologic Monitoring Facility, University <strong>of</strong> Chicago,<br />
Chicago, IL<br />
2<br />
Section <strong>of</strong> Hematology and Oncology, University <strong>of</strong> Chicago Medical<br />
Center, Chicago, IL<br />
INNATE IMMUNITY IN CANCER<br />
105<br />
ROLE OF NK AND NKT CELLS IN BREAST CANCER<br />
PATIENTS: ASSOCIATION WITH FAVORABLE<br />
PROGNOSIS<br />
Maria Libera Ascierto 1,4 , Kyle K. Payne 2 , Maciej Kmieciak 2 , Michael O.<br />
Idowu 3 , Catherine Dumur 3 , Davide Bedognetti 1 , Andrea De Maria 4 ,<br />
Ena Wang 1 , Francesco M. Marincola 1 , Masoud H. Manjili 2<br />
1<br />
Infectious Disease and Immunogenetics Section (IDIS), Department<br />
<strong>of</strong> Transfusion Medicine and Center <strong>for</strong> Human Immunology, National<br />
Institutes <strong>of</strong> Health, Bethesda, MD<br />
2<br />
Department <strong>of</strong> Microbiology & Immunology, Virginia Commonwealth<br />
University Massey <strong>Cancer</strong> Center, Richmond, VA<br />
3<br />
Department <strong>of</strong> Pathology, Virginia Commonwealth University Massey<br />
<strong>Cancer</strong> Center, Richmond, VA<br />
4<br />
Istituto G. Gaslini, Genova, Italy<br />
106<br />
GENOTYPIC, PHENOTYPIC AND FUNCTIONAL<br />
ANALYSIS OF MELANOMA<br />
Valeria De Giorgi 1 , Quizhen Lui 1 , Zoltan Pos 2 , John Wunderlich 3 ,<br />
Tara L. Spivey 1 , Lorenzo Uccellini 1 , Maria Libera Ascierto 1 , Davide<br />
Bedognetti 1 , Ena Wang 1 , Francesco M. Marincola 1<br />
1<br />
Department <strong>of</strong> Transfusion Medicine, National Institutes <strong>of</strong> Health,<br />
Bethesda, MD<br />
2<br />
Department <strong>of</strong> Genetics, Cell- and Immunobiology, Semmelweis<br />
University, Budapest, Hungary<br />
3<br />
Surgery Branch, NCI, National Institutes <strong>of</strong> Health, Bethesda, MD<br />
68<br />
<strong>FINAL</strong> <strong>PROGRAM</strong> • SITC 26 TH ANNUAL MEETING<br />
November 4-6, 2011 • North Bethesda, MD • www.sitcancer.org
Change language